Novartis Q1 Preview: Profits Still Under Pressure From Lockdown
Entresto Sales Should Be Strong But Cosentyx May Struggle
Executive Summary
The company will review a challenging quarter next week when its financials will reveal that certain parts of the business are still feeling the effects of the COVID-19 pandemic, its eye drugs in particular.
You may also be interested in...
Novartis's Targeted Radioligand Improves OS And PFS In Prostate Cancer
Novartis’s PSMA-targeted radioligand has improved overall survival and progression-free survival in top-line results from the Phase III VISION study in prostate cancer, cementing the company's pioneering role in the therapeutic area.
Novartis Teams Up With CureVac To Make COVID-19 Vaccine
The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.
Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker